RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
RT @TumorBoardTues: 5/8 #TumorBoardTuesday Friday Case🎀 Gem/cis→stable dz for a while G2✋🏽🦶🏽neuropathy! Transition to FOLFIRI. But: 😱Re…
RT @TumorBoardTues: 6/8 #TumorBoardTuesday Friday Case🎀 Which led to @W_Park_MD’s mini-tweetorial about post-gemcitabine tx options in #CC…
RT @TumorBoardTues: 6/8 #TumorBoardTuesday Friday Case🎀 Which led to @W_Park_MD’s mini-tweetorial about post-gemcitabine tx options in #CC…
RT @TumorBoardTues: 5/8 #TumorBoardTuesday Friday Case🎀 Gem/cis→stable dz for a while G2✋🏽🦶🏽neuropathy! Transition to FOLFIRI. But: 😱Re…
6/8 #TumorBoardTuesday Friday Case🎀 Which led to @W_Park_MD’s mini-tweetorial about post-gemcitabine tx options in #CCA, guided by NGS! https://t.co/Jt7eHswJD0
5/8 #TumorBoardTuesday Friday Case🎀 Gem/cis→stable dz for a while G2✋🏽🦶🏽neuropathy! Transition to FOLFIRI. But: 😱Repeat liquid NGS + RNA analysis shows FGFR-BICC1 fusion (the MOST common fusion in #CCA)!! 🤔What to do now❓ 💡✅FGFR inhibitor! https://t
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
RT @W_Park_MD: 9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqi…
9/12 #TumorBoardTuesday Mini-Tweetorial 5 👨🏫 Many FGFR inhibitors 💊Pemigatinib https://t.co/163squfYOj https://t.co/fg1Enqit19 💊Infigratinib https://t.co/25AvvZqBe6 https://t.co/zXji1wVzF3 💊Derazantinib https://t.co/VwqnXBqqYl 💊Futibatinib https://t.co/G
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study 4/4 https://t.co/Z8xn1snRdJ
RT @VivekSubbiah: 4/n FGFR 👉Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-labe…
RT @VivekSubbiah: 4/n FGFR 👉Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-labe…
4/n FGFR 👉Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study https://t.co/zQIUI5zXoC
5/x Insbesondere bei intrahepatischen CCC relevant - FGFR2 gerichtete Therapie mit Pemigatinib https://t.co/U885DlRrMG
RT @OncoViews: Pemigatinib approved by @NICEComms in the UK and will now be a treatment option for those with advanced FGFR2+ #cholangiocar…
RT @OncoViews: Pemigatinib approved by @NICEComms in the UK and will now be a treatment option for those with advanced FGFR2+ #cholangiocar…
RT @OncoViews: Pemigatinib approved by @NICEComms in the UK and will now be a treatment option for those with advanced FGFR2+ #cholangiocar…
Pemigatinib approved by @NICEComms in the UK and will now be a treatment option for those with advanced FGFR2+ #cholangiocarcinoma 💊 Press release ➡️ https://t.co/ozml24pz6y See the phase II study by @GABOUALFA and colleagues in @TheLancetOncol ➡️ http
RT @clearyonc: FGFR2 translocations are present in 15% of intrahepatic cholangiocarcinomas. A major milestone was the FDA approval of FGFR…
RT @clearyonc: FGFR2 translocations are present in 15% of intrahepatic cholangiocarcinomas. A major milestone was the FDA approval of FGFR…
RT @clearyonc: FGFR2 translocations are present in 15% of intrahepatic cholangiocarcinomas. A major milestone was the FDA approval of FGFR…
RT @clearyonc: FGFR2 translocations are present in 15% of intrahepatic cholangiocarcinomas. A major milestone was the FDA approval of FGFR…
RT @clearyonc: FGFR2 translocations are present in 15% of intrahepatic cholangiocarcinomas. A major milestone was the FDA approval of FGFR…
FGFR2 translocations are present in 15% of intrahepatic cholangiocarcinomas. A major milestone was the FDA approval of FGFR inhibitors in cholangiocarcinoma. The first FGFRi approved was pemigatinib. @gaboualfa @miteshborad @doccatenacci https://t.co/jxHi6
RT @doctorC369: This is your chance to ask Dr. Catenacci about the KEYNOTE-590 trial...what went down there!
RT @doctorC369: This is your chance to ask Dr. Catenacci about the KEYNOTE-590 trial...what went down there!
RT @doctorC369: This is your chance to ask Dr. Catenacci about the KEYNOTE-590 trial...what went down there!
RT @binayshah: If you want updates in GI oncology, do not miss this opportunity! Outstanding faculties @DocCatenacci @rachnatshroff @aparna…
RT @binayshah: If you want updates in GI oncology, do not miss this opportunity! Outstanding faculties @DocCatenacci @rachnatshroff @aparna…
RT @binayshah: If you want updates in GI oncology, do not miss this opportunity! Outstanding faculties @DocCatenacci @rachnatshroff @aparna…
RT @btfoundation: Dr. Daniel Catenacci @DocCatenacci from @UChicagoMed is speaking about gastroesophageal #Cancer THIS Sunday at our #GICan…
This is your chance to ask Dr. Catenacci about the KEYNOTE-590 trial...what went down there!
RT @binayshah: If you want updates in GI oncology, do not miss this opportunity! Outstanding faculties @DocCatenacci @rachnatshroff @aparna…
If you want updates in GI oncology, do not miss this opportunity! Outstanding faculties @DocCatenacci @rachnatshroff @aparna1024 @agrothey @GABOUALFA @AmanChauhanMD @JoeChaoMD @doctorC369 @SirohiBhawna @EileenMOReilly. If questions, contact Sam sam.m@binay
Dr. Daniel Catenacci @DocCatenacci from @UChicagoMed is speaking about gastroesophageal #Cancer THIS Sunday at our #GICancer #GISM conference! Register at https://t.co/q1BVbJWvwY Check out some projects he's contributed to: 1. https://t.co/Ik0x7ABXqK 2.
RT @TumorBoardTues: #TumorBoardTuesday Thursday🎀 (Case from 02/23/21) 4⃣None more "actionable" than FGFR fusions ✅2 perfect tweetorials on…
RT @TumorBoardTues: #TumorBoardTuesday Thursday🎀 (Case from 02/23/21) 4⃣None more "actionable" than FGFR fusions ✅2 perfect tweetorials on…
RT @TumorBoardTues: #TumorBoardTuesday Thursday🎀 (Case from 02/23/21) 4⃣None more "actionable" than FGFR fusions ✅2 perfect tweetorials on…
#TumorBoardTuesday Thursday🎀 (Case from 02/23/21) 4⃣None more "actionable" than FGFR fusions ✅2 perfect tweetorials on Tx in refractory Dz (w/1st line and neoadjuvant trials ongoing) on the activity of infigratinib https://t.co/agigx03hWb & pemigatin
RT @MalviSavani: Mini-Tweetorial #1 @rachnatshroff ✨FGFR alterations as a major🎯in #CCA 💡FLIGHT 202: Ph II Pemigatinib (FGFR1,2,3 inhib)…
RT @MalviSavani: Mini-Tweetorial #1 @rachnatshroff ✨FGFR alterations as a major🎯in #CCA 💡FLIGHT 202: Ph II Pemigatinib (FGFR1,2,3 inhib)…
RT @MalviSavani: Mini-Tweetorial #1 @rachnatshroff ✨FGFR alterations as a major🎯in #CCA 💡FLIGHT 202: Ph II Pemigatinib (FGFR1,2,3 inhib)…
RT @MalviSavani: Mini-Tweetorial #1 @rachnatshroff ✨FGFR alterations as a major🎯in #CCA 💡FLIGHT 202: Ph II Pemigatinib (FGFR1,2,3 inhib)…
RT @MalviSavani: Mini-Tweetorial #1 @rachnatshroff ✨FGFR alterations as a major🎯in #CCA 💡FLIGHT 202: Ph II Pemigatinib (FGFR1,2,3 inhib)…
RT @MalviSavani: Mini-Tweetorial #1 @rachnatshroff ✨FGFR alterations as a major🎯in #CCA 💡FLIGHT 202: Ph II Pemigatinib (FGFR1,2,3 inhib)…
RT @MalviSavani: Mini-Tweetorial #1 @rachnatshroff ✨FGFR alterations as a major🎯in #CCA 💡FLIGHT 202: Ph II Pemigatinib (FGFR1,2,3 inhib)…
Mini-Tweetorial #1 @rachnatshroff ✨FGFR alterations as a major🎯in #CCA 💡FLIGHT 202: Ph II Pemigatinib (FGFR1,2,3 inhib) in prev Tx CCA ❗️146 pts➡️3 CR, 35 PR ❗️1st FDA approved Tx for prev Tx locally advanced CCA w/ FGFR rearrangement/fusion 🧬 https:/
RT @VivekSubbiah: 7. Cholangiocarcinoma. Pemigatinib for FGFR & Dabrafenib+ Trametinib BRAFV600 + cholangiocarcinoma. Two @TheLancetOncol…
RT @VivekSubbiah: 7. Cholangiocarcinoma. Pemigatinib for FGFR & Dabrafenib+ Trametinib BRAFV600 + cholangiocarcinoma. Two @TheLancetOncol…
RT @VivekSubbiah: 7. Cholangiocarcinoma. Pemigatinib for FGFR & Dabrafenib+ Trametinib BRAFV600 + cholangiocarcinoma. Two @TheLancetOncol…
About 5% of cholangiocarcinomas are V600E BRAF mutant. This is the same percentage as those with 1p36 /ENO1 homozygous deletions and would be candidates for ENO2 inhibitor therapy. In other words, such a “high precision oncology” trial is fully feasible.
7. Cholangiocarcinoma. Pemigatinib for FGFR & Dabrafenib+ Trametinib BRAFV600 + cholangiocarcinoma. Two @TheLancetOncol publications. ( COI: PI of BRAF trial) https://t.co/O9Sl41kcq7 https://t.co/EnMlQOtRPL
RT @esinghimd: 6/ Finally, Dr. @MadhuEluri, reviewed the results of the ⚡️practice-changing FIGHT-202 trial resulting in @FDAOncology appro…
RT @esinghimd: 6/ Finally, Dr. @MadhuEluri, reviewed the results of the ⚡️practice-changing FIGHT-202 trial resulting in @FDAOncology appro…
6/ Finally, Dr. @MadhuEluri, reviewed the results of the ⚡️practice-changing FIGHT-202 trial resulting in @FDAOncology approval of PO pemigatinib in previously treated locally advanced/metastatic FGFR2+ cholangioca 🔗 https://t.co/F2roRMKdAC @TheLancetOncol
RT @m0370: ペミガチニブって第3相はやってないんだっけ?(第2相はFIGHT-202試験というのをやってFGFR1-3まで対象にしてFGFR2だけポジティブだったぽい /lancet oncol https://t.co/q3NaOkSzWz )
ペミガチニブって第3相はやってないんだっけ?(第2相はFIGHT-202試験というのをやってFGFR1-3まで対象にしてFGFR2だけポジティブだったぽい /lancet oncol https://t.co/q3NaOkSzWz )
RT @TheLancetOncol: In the May issue: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcin…
RT @FlavioRochaMD: More promising news in the fight against #cholangiocarcinoma #mutationsmatter @curecc @HPBSurgeryatVM https://t.co/JYorK…
RT @FlavioRochaMD: More promising news in the fight against #cholangiocarcinoma #mutationsmatter @curecc @HPBSurgeryatVM
RT @TheLancetOncol: In the May issue: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcin…
RT @TheLancetOncol: In the May issue: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcin…
RT @TheLancetOncol: In the May issue: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcin…
RT @TheLancetOncol: In the May issue: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcin…
RT @TheLancetOncol: In the May issue: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcin…
RT @FlavioRochaMD: More promising news in the fight against #cholangiocarcinoma #mutationsmatter @curecc @HPBSurgeryatVM https://t.co/JYorK…
RT @TheLancetOncol: In the May issue: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcin…
RT @FlavioRochaMD: More promising news in the fight against #cholangiocarcinoma #mutationsmatter @curecc @HPBSurgeryatVM
RT @kmody29: Pemigatinib APPROVED! @Incyte @FDAOncology The first targeted therapy specifically approved for #cholangiocarcinoma @curecc ht…
RT @FlavioRochaMD: More promising news in the fight against #cholangiocarcinoma #mutationsmatter @curecc @HPBSurgeryatVM https://t.co/JYorK…
RT @TheLancetOncol: In the May issue: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcin…
RT @TheLancetOncol: In the May issue: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcin…
RT @TheLancetOncol: In the May issue: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcin…
RT @FlavioRochaMD: More promising news in the fight against #cholangiocarcinoma #mutationsmatter @curecc @HPBSurgeryatVM
Great to see that we begin to tackle another devastating disease that was lingering in the shadows of #oncology for a long time. #PrecisionMedicine
RT @TheLancetOncol: In the May issue: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcin…
RT @FlavioRochaMD: More promising news in the fight against #cholangiocarcinoma #mutationsmatter @curecc @HPBSurgeryatVM
More promising news in the fight against #cholangiocarcinoma #mutationsmatter @curecc @HPBSurgeryatVM
In the May issue: phase 2 study of #pemigatinib for previously treated, locally advanced or metastatic #cholangiocarcinoma https://t.co/4TzHY5zdL7 https://t.co/QGlPBr2BWo
RT @NaultJc: Interesting data about FGFR fusion inhibition in cholangiocarcinoma. Waiting for the phase 3. https://t.co/viONAxGjyS
Interesting data about FGFR fusion inhibition in cholangiocarcinoma. Waiting for the phase 3. https://t.co/viONAxGjyS
CHOLANGIO: phase 2 data now published supporting the FDA's recent approval of pemigatinib for previously treated advanced FGFR2-rearranged tumours (ORR 36%). Responses were not seen in subjects with other FGF/FGFR alterations. https://t.co/iGMnSuP9Ce
@askrenal @NephJC @kdjhaveri Serum phosphate? proteinuria? AKI is an adverse event that leads to discontinuation. https://t.co/sOHa8qtFHu
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @MarkGeyerMD: Hope FIGHT-203 continues to show promising results w/ pemigatinib in myeloid/lymphoid neoplasms w/ eosinophilia and FGFR1…
Hope FIGHT-203 continues to show promising results w/ pemigatinib in myeloid/lymphoid neoplasms w/ eosinophilia and FGFR1 rearrangement as well!
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…
RT @BenWestphalen: Just as a reminder. In the May 1st issue of @TheLancetOncol - Arndt Vogel & colleagues report the results from the phas…